20 June 2013
Keywords: Ligand Pharma, Retrophin. Orphan kidney disease indicationa, DARA
Article | 21 February 2012
USA-based Ligand Pharmaceuticals (Nasdaq: LGND) has entered into an agreement in which it has licensed rights to DARA (a Dual ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
21 February 2012
19 June 2013
© 2013 thepharmaletter.com